Bajaj Healthcare Q3 profit up 34% YoY; 4 promoter family directors re-appointed

Promoter Family Board EntryManagement Changes View source PDF Explain this filing

BAJAJHCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.3%Reaction day

₹389.30

prior close

₹395.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.3%+1.0% vs market

Pharmaceuticals peers, median of 158sector-0.8%+0.5% vs sector

On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+5.3

10m

+1.3

15m

+2.0

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.3-1.3+1.0-0.8+0.5

Next day

-5.0-4.0-1.0-3.1-1.9

-7.0-4.8-2.2-4.1-2.9

-7.8-3.3-4.5-2.9-4.9

-10.6-5.3-5.3-4.3-6.3

-14.0-5.2-8.8-4.6-9.4

-6.8-3.7-3.1-4.0-2.7

15d

-2.4+3.6-6.0-1.1-1.3

-8.2+0.1-8.3-2.4-5.7

-22.2-8.9-13.3-9.4-12.7

-14.7+3.2-17.9-1.0-13.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q3 FY26 revenue rose 31% YoY to Rs 161.22 cr; PAT up 34% YoY to Rs 15.67 cr. Nine-month revenue Rs 457.97 cr. Board re-appointed 4 promoter family directors - CMD Sajankumar Bajaj, MD Anil Jain, WTD Namrata Bajaj (CMD), and WTD Pakshal Jain (MD) - for 3-year terms from April or June 2026, pending shareholder approval via postal ballot.

Likely market impact

Strong Q3 results show business growth. Re-appointments keep promoter family in control at the board; needs shareholder vote.